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Abstract. Melanoma is an aggressive skin cancer and its 
incidence is increasing faster than any other type of cancer. 
Whilst dacarbazine (DTIC) is the standard chemotherapy for 
metastatic melanoma, it has limited success. Statins, including 
pitavastatin, have been demonstrated to have a range of anti-
cancer effects in a number of human cancer cell lines. The 
present study therefore explored the anti-cancer activity of 
combined DTIC and pitavastatin in A375 and WM115 human 
melanoma cells. Cell survival assays demonstrated that 
combined DTIC and pitavastatin treatment resulted in syner-
gistic cell death. Cell cycle analyses further revealed that this 
combined treatment resulted in a G1 cell cycle arrest, as well 
as a sub-G1 population, indicative of apoptosis. Activation of 
apoptosis was confirmed by Annexin V-fluorescein isothio-
cyanate/propidium iodide double-staining and an increase in 
the levels of active caspase 3 and cleaved poly (ADP-ribose) 
polymerase. Furthermore, it was demonstrated that apoptosis 
occurs through the intrinsic pathway, evident from the release 
of cytochrome c. Finally, combined DTIC and pitavastatin 
treatment was demonstrated to also activate autophagy as part 
of a cell death mechanism. The present study provides novel 
evidence to suggest that the combined treatment of DTIC and 
pitavastatin may be effective in the treatment of melanoma.
Introduction
Melanoma is a particularly aggressive skin cancer and its inci-
dence is increasing faster than any other cancer worldwide (1). 
At present, the 10-year survival rate of patients diagnosed with 
advanced (stage IV) metastatic melanoma is <10% (2), which 
highlights the importance of early detection and treatment. 
The Food and Drug Administration approved the chemo-
therapeutic agent dacarbazine (DTIC) for the treatment of 
metastatic melanoma in 1975, and it remains the only licensed 
chemotherapeutic agent in use today (1). DTIC is a methyl-
ating agent which causes DNA damage, cell cycle arrest and 
apoptosis. Despite this, only 2% of all patients with metastatic 
melanoma receiving this treatment demonstrate a significant 
response and only 11.2% demonstrate a partial response (3). 
Resistance to DTIC has been associated with the upregula-
tion of pro-survival signals and anti-apoptotic molecules in 
cancer cells. Despite its moderate effects, DTIC continues to 
be the standard treatment for metastatic melanoma as no other 
chemotherapeutic treatment has been demonstrated to have a 
significantly increased chance of survival when compared with 
DTIC (4,5). Provided the limited efficacy of the current meta-
static melanoma chemotherapies in addition to the increasing 
incidence of melanoma cases, there appears to be a need for 
the development of more effective treatment strategies.
Statins are a group of drugs commonly used for the 
reduction of cholesterol levels (6). They work by inhibiting 
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, a critical 
enzyme in the mevalonate pathway, which is responsible 
for cholesterol synthesis (6,7). In addition, statins have been 
demonstrated to serve a function in immune regulation and 
cancer prevention (8). Evidence from in vitro and in vivo studies 
has revealed that statins have a wide range of anticancer activi-
ties in various types of cancer (6,9,10). In multiple myeloma 
cells, simvastatin has been demonstrated to induce S phase 
cell cycle arrest through the downregulation of cell division 
cycle 25a, cyclin A and cyclin dependent kinase expression 
and the activation of checkpoint kinase 1 (9). This cell cycle 
arrest was accompanied by intrinsic apoptosis as demonstrated 
by diminished B-cell lymphoma 2 (Bcl-2) protein levels, 
increased cytosolic cytochrome c and active caspase 9 and 
caspase 3 levels. In human glioblastoma cells, previous studies 
have revealed that erivastatin, pitavastatin and fluvastatin are 
potent anti-proliferative agents (10,11). In addition, one clinical 
trial revealed that fluvastatin reduced tumour proliferation and 
increased apoptotic activity in high-grade, stage 0/1 breast 
cancer (12). Pitavastatin has been demonstrated to exert a cyto-
toxic effect on U87 glioblastoma tumour growth in vivo (10). 
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On a molecular level, pitavastatin treatment has been demon-
strated to upregulate the cell cycle regulator p21 and to inhibit 
nuclear factor-κB (NF-κB) in different tumour cells, which 
resulted in cell cycle arrest and apoptosis (13,14). Finally, in 
glioma cells, autophagic cell death was demonstrated to be a 
potential mechanism of pitavastatin-induced cytotoxicity by 
also resulting in the inhibition of NF-κB (15). However, the 
exact molecular mechanisms underpinning the anticancer 
activity of pitavastatin remain mostly unknown.
Given the shortage of treatments for metastatic melanoma, 
the present study therefore aimed to explore the effects of 
combined pitavastatin and DTIC treatment in human mela-
noma cells. The present study demonstrated that this combined 
treatment results in the synergistic inhibition of cell survival 
and further demonstrated that this occurs through the induc-
tion of intrinsic apoptosis and autophagy cell death pathways.
Materials and methods
Cell culture and treatments. The human melanoma cell lines 
A375 and WM115, sourced from the Department of Human 
Biology, University of Cape Town (Cape Town, South Africa), 
were maintained in Dulbecco's modified Eagle's medium, 
Biological Industries Israel Beit-Haemek (Kibbutz Beit-
Heamek, Israel) supplemented with 10% foetal bovine serum, 
Biological Industries Israel Beit-Haemek in a humidified 5% 
CO2 balanced air incubator at 37˚C. Pitavastatin (Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA) and DTIC (Sigma-
Aldrich, Merck KGaA, Darmstadt, Germany) were dissolved 
in dimethyl sulfoxide (DMSO) to give stock concentrations of 
5 mM, which were stored for no more than 5 days. Control 
cells were treated with equivalent concentrations of DMSO 
(vehicle). Autophagy inhibitor 3-methyl adenine (10 mM) 
(3MA; Sigma-Aldrich; Merck KGaA) was added at 37˚C for 
1 h prior to pitavastatin/DTIC treatment.
Cytotoxicity assays. Cells were seeded in 96-well plates at 
a density of 4x103-5x103 cells per well and allowed to settle 
for 48 h at 37˚C. Cells were treated with a range of pitavas-
tatin (0-5.0 µM) and/or DTIC (0.0-100 µM) concentrations 
or vehicle for 48 h at 37˚C. Cytotoxicity was assessed using 
an MTT assay kit as per the manufacturer's protocol (Roche 
Diagnostics GmbH, Mannheim, Germany) (16). Briefly, 10 µl 
MTT solution was added to each well and cells were incubated 
at 37˚C for 4 h, followed by addition of 100 µl solubilisation 
buffer [10% SDS; Sigma-Aldrich; Merck KGaA) in 0.01 M 
hydrochloric acid (HCl) (Sigma-Aldrich, Israel)] and incuba-
tion for 16 h at 37˚C. Absorbance at 585 nm was determined 
for each well and the mean cell viability was calculated as a 
percentage of the mean vehicle control.
Cell cycle analysis. Cells were plated at a density of 3x105-
4x105 cells per 6-cm dish and allowed to settle for 24 h at 
37˚C. Log-phase cultures were exposed to drugs or vehicle 
for 48 h at 37˚C. Cells were then trypsinised, washed with 
PBS and fixed in 95% ethanol at 4˚C overnight, followed by 
RNase A (50 µg/ml; Sigma-Aldrich; Merck KGaA) treatment 
for 15 min at 37˚C and and immediately stained for 30 min at 
room temperature with propidium iodide (PI; Sigma-Aldrich; 
Merck KGaA). Cellular DNA content was determined using 
flow cytometry with individual samples subjected to a 
FACSCalibur flow cytometer with a 488 nm coherent laser 
(BD Biosciences, San Jose, CA, USA). Cellquest Pro version 
5.2.1 software (BD Biosciences) was used for data acquisi-
tion and analyses were performed using Modfit version 2.0 
software (BD Biosciences).
Apoptosis detection. Log-phase melanoma cultures were 
treated with 1.0 µM pitavastatin, 40.0 µM DTIC, combined 
pitavastatin (1.0 Μm)-DTIC (40.0 µM) or vehicle for 48 h 
at 37˚C. Adherent and floating cells were collected and 
double-labelled with Annexin V-Fluorescein isothiocyanate 
(FITC) and PI using Annexin V-FITC Apoptosis Detection 
Kit (Sigma-Aldrich; Merck KGaA) as per the manufacturer's 
protocol. Annexin V-FITC was used to quantitatively deter-
mine the percentage of apoptotic cells while PI was used to 
stain all dead cells. Cells were analysed by flow cytometry 
with a 488 nm coherent laser equipped with FACStation 
running version 3.3 Cell Quest software (BD Biosciences).
Cytochrome c release. Melanoma cells treated as aforemen-
tioned with vehicle or pitavastatin-DTIC for 48 h at 37˚C were 
trypsinized, re-suspended in HB-7S buffer [1 mmol/l EGTA 
Na-free, 5 mmol/l Tris-HCl (pH 7.4), 1 mmol/l DTT, and 11% 
sucrose] (Sigma-Aldrich; Merck KGaA) and subcellular frac-
tions were collected as described previously (17).
Western blotting. Cells were harvested and the protein was 
prepared as described previously (16). Primary antibodies 
used were as follows: Anti-PARP1/2 (cat no. sc-7150), anti-p53 
(cat no. sc-126), anti-p21 (cat no. sc-756), anti-Bcl2-associated 
X, apoptosis regulator (Bax; cat no. sc-7480), anti-cyclin D (cat 
no. sc-753), anti-cytochrome c (cat no. sc-65396), anti-COXIV 
(cat no. sc-69359) and anti-cyclin E (cat no. sc-247; Santa Cruz 
Biotechnology, Inc.), anti-actin (cat. no., A4700; Sigma-Aldrich; 
Merck KGaA), anti-LC3-phosphatidylethanolamine conjugate 
(cat no. 2775), anti-BCL-2 (cat no. 2876), anti-Caspase-3 (cat 
no. 9661) and anti-Caspase-8 (cat no. 9746; Cell Signaling 
Technology, Inc., Danvers, MA, USA). Following primary anti-
body incubation, membranes were incubated with appropriate 
horseradish peroxidase-conjugated secondary antibodies 
(1:5,000; Bio-Rad Laboratories, Inc.,) and antibody-reactive 
proteins were visualized using the electrochemiluminescence 
reaction detection system as previously described (Thermo 
Fisher Scientific, Inc., Waltham, MA, USA) (18).
Autophagy assays. Autophagy was confirmed by the presence 
of fluorescent puncta in cells transfected with a green fluo-
rescence protein (GFP)-light chain 3 LC3) expression vector 
(cat. no., 24920; Addgene, Inc., Cambridge, MA, USA), as 
previously described (16).
Statistical analysis. Results are presented as the mean ± stan-
dard error of the mean (SEM) of the three independent 
experiments. Statistical analysis of data was performed using 
the two-sample t-test in Microsoft Excel 2013 (Microsoft 
Corporation, Redmond, WA, USA) or a one-way ANOVA 
with Tukey's post hoc test in Graph Pad Prism v.5. (GraphPad 
Software, Inc., La Jolla, CA, USA). P<0.05 was considered to 
indicate a statistically significant difference.
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Results
Pitavastatin and DTIC synergistically inhibit melanoma cell 
survival. To investigate the anti-cancer effect of pitavastatin 
on melanoma, human A375 and WM115 melanoma cells were 
treated with increasing concentrations (0-5 µM) of pitavastatin 
for 48 h. An MTT assay was used to determine cell viability 
and a dose-dependent decrease in cell survival was observed 
in A375 and WM115 cells (Fig. 1A). The results revealed that 
4 µM pitavastatin treatment resulted in the death of >50% of 
cells, suggesting that it exerts potent cytotoxic effects against 
melanoma cells specifically at high concentrations. DTIC has 
previously been demonstrated to inhibit A375 cell survival but 
only at a high concentrations of 25-100 µM (19). Therefore, 
the present study aimed to determine whether the combined 
treatment of pitavastatin and DTIC may have a greater anti-
cancer effect on A375 and WM115 cells. To this end, cells were 
treated with 1 µM pitavastatin for 1 h followed by treatment 
with increasing concentrations (10-100 µM) of DTIC for 48 h. 
Fig. 1B and C demonstrate that the combined treatment resulted 
in enhanced anti-cytotoxic activity compared with DTIC treat-
ment alone. Whilst 40 µM DTIC resulted in the death of <15% 
of melanoma cells, when cells were pre-treated with 1 µM 
pitavastatin, it resulted in the death of ~50% of melanoma cells 
at the same DTIC concentration. The results of the present 
study demonstrate that combined pitavastatin and DTIC treat-
ment results in a synergistic cytotoxic effect in melanoma cells.
Combined pitavastatin and DTIC treatment induces G1 cell 
cycle arrest in melanoma cells. The present study aimed to 
investigate the mechanism by which combined pitavastatin-
DTIC treatment synergistically inhibits melanoma cell 
survival. To this end, A375 and WM115 cells were treated with 
vehicle, pitavastatin (1.0 µM), DTIC (40.0 µM) or pitavastatin-
DTIC (1.0 and 40.0 µM, respectively) and the effect on the 
cell cycle profile was determined by flow cytometry. Fig. 2A 
demonstrates that combined pitavastatin-DTIC treatment 
induced a significantly greater G1 cell cycle arrest than either 
treatment alone. To further explore this, A375 and WM115 
cells were treated with pitavastatin and DTIC and markers of 
cell cycle arrest were analysed by the use of western blotting. 
Fig. 2B demonstrates the p53 response elicited by combined 
pitavastatin-DTIC treatment. In the two cell lines, treatment 
with only pitavastatin resulted in an increase in p21 levels, 
however, when WM115 cells were treated with pitavastatin-
DTIC, p21 levels were even further increased. For A375 and 
WM115 cells pitavastatin-DTIC treatment corresponded with 
a decrease in cyclin D1 and cyclin E1, which are required 
for the transition from G1 to S phase. These results provide 
compelling evidence that combined pitavastatin-DTIC treat-
ment results in G1 cell cycle arrest in melanoma cells.
Combined pitavastatin-DTIC treatment activates intrinsic 
apoptosis. The presence of sub-G1 peaks on DNA content histo-
grams is generally accepted to represent apoptotic cells (20). 
As cell cycle analysis demonstrated that combined pitavas-
tatin-DTIC treatment resulted in sub-G1 peaks (Fig. 2A), the 
present study aimed to determine whether pitavastatin-DTIC 
treatment induced cell death by apoptosis. To this end, A375 
and WM115 cells were treated with pitavastatin-DTIC and 
western blotting was performed to assess PARP cleavage and 
active caspase 3 levels, which are molecular markers of apop-
tosis. Fig. 3A demonstrates that levels of the active cleaved 
PARP and caspase 3 proteins notably increased in response 
to combined pitavastatin-DTIC treatment, suggesting that 
apoptosis is indeed activated.
Apoptosis may be activated through two main pathways, 
namely the extrinsic and intrinsic pathways (21). Whilst 
extrinsic apoptosis is mediated by death receptors and char-
acterized by caspase 8 activation (22), intrinsic apoptosis is 
mitochondria mediated and usually triggered by intracellular 
signals including hypoxia and DNA damage (23). During 
intrinsic apoptosis, the overexpression of pro-apoptotic Bcl-2 
proteins disrupts the mitochondrial membrane and eventually 
leads to the release of cytochrome c (24). In order to determine 
Figure 1. Pitavastatin and DTIC synergistically inhibit melanoma cell 
survival. (A) Cell survival rate as measured by an MTT assay of A375 and 
WM115 cells treated with increasing concentrations of pitavastatin (0.0-
5.0 µM) or vehicle. (B) A375 and (C) WM115 cells treated with 1.0 µM 
pitavastatin and then treated with increasing concentrations (10.0-100.0 µM) 
of DTIC. Results are presented as the mean percentage ± standard error of 
the mean of untreated cells and represent the pooled results of at least three 
experiments performed in quadruplicate. DTIC, dacarbazine.
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whether combined Pitavastatin-DTIC treatment activated 
either one of the apoptotic pathways, levels of intrinsic and 
extrinsic apoptotic molecular markers were measured by 
western blotting. The results of the present study demonstrate 
that combined pitavastatin-DTIC treatment did not acti-
vate the pro-apoptotic factor caspase 8, suggesting that the 
extrinsic apoptotic pathway is not activated (data not shown). 
On the other hand, combined pitavastatin-DTIC treatment 
induced expression of the intrinsic pro-apoptotic factor Bax 
and decreased expression of the anti-apoptotic protein Bcl-2. 
Furthermore, Fig. 3B demonstrates that pitavastatin-DTIC 
treatment led to a notable increase in cytoplasmic cytochrome 
c protein levels and a notable decrease in mitochondrial cyto-
chrome c protein level in A375 cells. Cytochrome oxidase IV 
was used as a mitochondrial marker and actin was detected 
as a marker for cytoplasmic fraction. Collectively, the results 
of the present study demonstrate that combined pitavastatin-
DTIC treatment induces cell death through intrinsic apoptosis 
in melanoma cells.
Combined pitavastatin-DTIC treatment induces autophagy. 
Increasing evidence has revealed that autophagy is activated 
in response to statins (25) and large vacuoles indicative of 
autophagy were observed in A375 and WM115 cells treated 
with pitavastatin alone or and pitavastatin-DTIC combined (data 
not shown). In order to explore this, protein extracts from cells 
treated with pitavastatin, DTIC, pitavastatin-DTIC or vehicle 
were assessed for LC3II, a molecular marker of autophagy, by 
western blotting. Fig. 4A demonstrated that pitavastatin alone 
or in combination with DTIC induces high levels of LC3II. 
In order to further confirm that combined pitavastatin-DTIC 
treatment induces autophagy, A375 and WM115 cells were 
transiently transfected with a GFP-LC3 expression vector and 
autophagosome formation was monitored by confocal micros-
copy. As a result, the combined treatment of pitavastatin-DTIC 
led to a significant accumulation of GFP-LC3 puncta (Fig. 4B).
Whilst previous studies have suggested that chemotherapy 
may induce cell death via apoptosis and autophagy (26), other 
studies have demonstrated that this may induce autophagy, which 
attenuates apoptosis leading to drug resistance (27). Therefore, 
the present study examined, using Annexin V assays, whether 
the pitavastatin-DTIC-induced autophagy is a cell death or a cell 
survival mechanism. Fig. 4C demonstrates that pharmacological 
inhibition of autophagy, through the use of 3MA, significantly 
reduced the cytotoxicity and the total cell death induced by 
combined pitavastatin-DTIC treatment. Taken together these 
observations suggest that pitavastatin-DTIC induced autophagy 
favours cell death and contributes to cytotoxicity.
Discussion
Malignant melanoma incidence is rapidly increasing and has 
almost doubled in the previous decade (2). Whilst DTIC chemo-
therapy is the standard treatment, <20% of patients respond at 
all to the treatment and <5% continue to respond to long-term 
treatment (28,29). Previous studies have demonstrated that, in 
Figure 2. Combined pitavastatin and DTIC treatment induces G1 cell cycle arrest in melanoma cells. (A) Cell cycle analysis of A375 and WM115 cells 
treated with vehicle, pitavastatin (1.0 µM), DTIC (40.0 µM) or pitavastatin-DTIC (1.0 and 40.0 µM, respectively). The proportion of cells at G0/G1 phase was 
expressed as a percentage of the total number of cells analysed and presented in the graphs as the mean ± standard error of the mean of three independent 
experiments (*P<0.01 as compared with vehicle, one-way ANOVA with Tukey's post hoc test). (B) A375 and WM115 cells were treated with 1.0 µM pitavas-
tatin, 40.0 µM DTIC, pitavastatin-DTIC (1.0 and 40.0 µM, respectively) or vehicle. Protein extracts were analysed by SDS-PAGE (8-15%) and western blotting 
using antibodies against p53, p21, Cyclin E1 and Cyclin D1. Actin was detected as a loading control. DTIC, dacarbazine.
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the case of melanoma, resistance to DTIC is associated with 
low levels of apoptosis and increasing levels of anti-apoptotic 
proteins (19,29,30).
Statins, which are anti-lipid agents, have been demonstrated 
to exert anti-proliferative and anti-cancer effect against a 
range of types of tumour (9,15,31). The present study there-
fore explored the in vitro efficacy of a combined treatment of 
DTIC with pitavastatin in human melanoma. The results of the 
present study provide several lines of evidence to suggest that 
pitavastatin may synergistically enhance the anti-cancer effects 
of DTIC. The half-maximal inhibitory concentration (IC50) of 
DTIC in several melanoma cell lines, including A375, A875, 
SB2, MeWo, B16-F1 and SK-MEL-5, has been demonstrated 
to be relatively high at >100 µM (5,32). Similar results were 
also obtained from the present study, where the IC50 of DTIC 
in the A375 and WM115 cell lines was >100 µM. On the other 
hand, pitavastatin has also been demonstrated to be cyto-
toxic on glioma, breast, myeloma and colon cancer with IC50 
values of <10 µM (9,10,15). Whilst previous studies have not 
described the cytotoxic effect of pitavastatin on melanoma cells, 
the present study demonstrates that pitavastatin is cytotoxic in 
melanoma cells and treatment with 4 µM pitavastatin results 
in ~50% cell death. The present study further demonstrated 
that melanoma cells pre-treated with pitavastatin (1 µM) are 
sensitised to DTIC (40 µM) resulting in ~50% cell death.
Furthermore, the present study revealed that the mechanism 
of action by which pitavastatin-DTIC combined treatment 
inhibits melanoma growth involves cell cycle arrest, apoptosis 
and autophagy. Previous studies have indicated that high doses 
of DTIC (2 mM) result in the death of cancer cells through 
apoptosis (33). In addition, in uveal melanoma cell lines, DTIC 
treatment (5 µg/ml) primarily led to cell cycle arrest in the G1 
phase (34). Another previous study demonstrated that DTIC 
(1 mM) induces S-phase cell cycle arrest in A375 cells and 
results in a slight increase in the sub-G1 peak (35). The same 
previous study demonstrated that melanoma cells exposed to 
parthenolide, a sesquiterpene lactone derived from the leaves of 
feverfew (Tanacetum parthenium), combined with 2 mM DTIC 
accumulated in the G2/M phase. Notably, pitavastatin was also 
demonstrated to inhibit the proliferation of human U937 mono-
cytic tumour cells in a dose-dependent manner and to induce 
S-phase cell cycle arrest (14). According to the same previous 
study, pitavastatin upregulated p21 protein levels but did not 
affect the expression levels of cyclin D1. The results of the 
present study reveal that whilst cells treated with DTIC (40 µM) 
demonstrated slight alterations to the cell cycle profile, combined 
pitavastatin-DTIC treated cells accumulated in the G1 phase as 
evidenced by flow cytometry and cell cycle regulator analyses. 
The results of the present study suggest that the induction of 
cell cycle arrest by DTIC may be concentration dependent and 
that pitavastatin enhances the ability of DTIC to halt cell cycle 
progression. Furthermore, the present study demonstrated that 
the cytotoxic effect of pitavastatin-DTIC includes the induc-
tion of apoptosis. Notably, whilst DTIC treatment (40 µM) did 
not induce apoptosis, combined pitavastatin-DTIC treatment 
resulted in significant levels of apoptosis as evidenced by the 
Figure 3. Combined treatment of pitavastatin-DTIC activates intrinsic apoptosis. (A) A375 and WM115 cells were treated with either vehicle, 1.0 µM pitavas-
tatin, 40.0 µM DTIC or pitavastatin-DTIC (1.0 and 40.0 µM, respectively). Protein extracts were analysed by SDS-PAGE (8-15%) and western blotting using 
antibodies to cleaved PARP, active caspase 3, Bax and Bcl-2. Actin was detected as a loading control. (B) Protein extracts from mitochondrial and cytoplasmic 
fractions were prepared from A375 cells treated with vehicle or Pitavastatin-DTIC (1.0 and 40.0 µM, respectively), resolved by SDS-PAGE (8-15%) and probed 
with the anti-cytochrome c, Cox IV and actin antibodies. DTIC, dacarbazine; CoxIV, cyclooxygenase IV; Bax, Bcl-2 associated X, apoptosis regulator; Bcl-2, 
B-cell lymphoma 2; PARP, poly (ADP-ribose) polymerase.
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increased level of apoptosis markers, cleaved PARP and active 
caspase 3, as well as annexin V staining. The results of the 
present study are in agreement with a number of studies which 
demonstrate that high concentrations of DTIC are necessary to 
induce apoptosis in melanoma cells (19,32,36). Whilst there has 
been insufficient research to determine which type of apoptosis 
is induced by DTIC, sensitization to the intrinsic apoptotic 
pathway has been revealed to augment DTIC-induced melanoma 
tumour cell death (37). In accordance with these observations, 
the results of the present study suggest that pitavastatin treat-
ment may enhance DTIC cytotoxicity through augmentation of 
the intrinsic apoptosis pathway.
Furthermore, the results of the present study demonstrated 
that melanoma cells treated with combined pitavastatin-
DTIC expressed a high level of L3II, a marker of autophagy. 
Chemical inhibition of autophagy resulted in enhancement 
of cell viability, suggesting that pitavastatin-DTIC-induced 
autophagy occurs as a cell death mechanism. In support of 
this, previous studies have suggested that DTIC and pitavas-
tatin may serve a function in the induction of autophagy and 
specifically as a mode of cell death (15,19,38).
In summary, results from the present study suggest 
that the combined treatment of pitavastatin-DTIC provides 
a synergistic anti-cancer effect through apoptosis and 
Figure 4. Combined pitavastatin-DTIC treatment induces autophagy. (A) A375 and WM115 cells were treated with either vehicle, 1.0 µM pitavastatin, 40.0 µM 
DTIC or Pitavastatin-DTIC (1.0 and 40.0 µM, respectively). Protein extracts were analysed using SDS-PAGE (8-15%) and western blotting using antibodies 
against LC3II and actin was used as a loading control. (B) A375 and WM115 cells were transiently transfected with a GFP-LC3 plasmid and treated with 
vehicle or pitavastatin-DTIC (1.0 and 40.0 µM, respectively). Autophagy was quantified by counting the number of GFP-LC3 puncta in twenty fields of view at 
magnification, x400, and dividing by the total number of transfected cells within these fields. The number of GFP-LC3 puncta/cell are presented in the graphs 
as the mean ± standard error of the mean of three independent experiments (*P<0.001 as compared with vehicle, Student's t-test). (C) Annexin V/propidium 
iodide double staining assay presenting the percentage of cell death induced by pitavastatin-DTIC when autophagy was inhibited by 10 mM 3-methyladenine 
and cells treated with pitavastatin-DTIC. (*P<0.05 with comparisons indicated by lines, Student's t-test). DTIC, dacarbazine; GFP, green fluorescence protein; 
LC3II, LC3-phosphatidylethanolamine conjugate; LC3, light chain 3.
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autophagy, and this should be further examined for mela-
noma treatment.
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